25 July 2017
Reporter: Mark Dugdale

Amphastar dodges hefty damages award

Amphastar Pharmaceuticals has sidestepped a potential $900 million payout after a District of Massachusetts jury invalidated the patent asserted against it.

Momenta Pharmaceuticals and Sandoz claimed that Amphastar's testing of its generic enoxaparin sodium blood thinner infringed their patent, but on 21 July the US District Court for the District of Massachusetts jury found it invalid for lack of enablement and adequate written description.

The pharmaceutical companies demanded more than $900 million in damages when they filed the patent infringement suit in 2011.

After the two-week trial, the jury also found that Momenta and Sandoz had waived their ability to enforce the patent against Amphastar due to their inequitable conduct before the US Pharmacopeial Convention.

Craig Wheeler, president and CEO of Momenta, said the company is considering launching an appeal.

“We are disappointed in the jury's verdict and believe the facts and the law do not support these findings. We are considering all available legal options to overturn the verdict, including post-trial motions and appeals,” said Wheeler.

“We continue to believe in the importance of investing in innovative techniques for bringing products to market and protecting those innovations from unauthorised use.”

Amphastar CEO Dr Jack Zhang said: “We have always believed that the facts and the law do not support the plaintiffs’ baseless allegations and we are very pleased that justice has prevailed. We remain proud of our technology for product development and will continue to execute on our mission of developing and manufacturing life-saving drugs for the benefit of patients.”

More news
The latest news from IPPro Patents
Join Our Newsletter

Sign up today and never
miss the latest news or an issue again

Subscribe now
EU Commission should prohibit use-based SEP licensing, says ACT
19 October 2017 | Brussels | Reporter: Barney Dixon
The App Association has called on the European Commission to prohibit any form of use-based pricing of technology essential to the internet of things
SUEPO confirms position on Campinos election
19 October 2017 | The Hague | Reporter: Barney Dixon
The Staff Union of the European Patent Office has confirmed its official position on the election of António Campinos as president of the European Patent Office
Withers & Rogers adds ten trainee attorneys
19 October 2017 | London | Reporter: Barney Dixon
International law firm Withers & Rogers has added ten new trainee attorneys covering both patents and trademarks
Apple to pay $439 million for FaceTime infringement
18 October 2017 | Texas | Reporter: Barney Dixon
Apple must pay VirnetX $439 million for infringing VirnetX patents with its FaceTime application
Restasis patents invalidated at Texas court
17 October 2017 | Texas | Reporter: Barney Dixon
Four patents relating to Allergan’s Restasis dry eye treatment have been invalidated by a US court, despite the pharmaceutical company’s patent transfer agreement with the Saint Regis Mohawk Tribe
Businesses should prepare for UPC, despite uncertainty
17 October 2017 | London | Reporter: Barney Dixon
Businesses should make preparations for the Unified Patent Court and unitary patent, despite mounting uncertainty surrounding when, if at all, the court will come into effect
Patent ‘irrationality’ causes a negative image of patents
16 October 2017 | London | Reporter: Barney Dixon
Spectators are far more accepting of copyright and trademarks than they are of patents because of “irrationality”, according to Sir Robin Jacob